Rocket Pharmaceuticals In...

NASDAQ: RCKT · Real-Time Price · USD
2.78
-0.14 (-4.79%)
At close: Jun 05, 2025, 3:59 PM
2.81
1.08%
Pre-market: Jun 06, 2025, 09:09 AM EDT

Rocket Pharmaceuticals Statistics

Share Statistics

Rocket Pharmaceuticals has 107.74M shares outstanding. The number of shares has increased by 17.46% in one year.

107.74M
17.46%
0.28%
99.99%
n/a
485
0.01%

Short Selling Information

The latest short interest is 13.94M, so 12.94% of the outstanding shares have been sold short.

13.94M
12.94%
25.23%
3.98

Valuation Ratios

The PE ratio is -4.61 and the forward PE ratio is -1.74. Rocket Pharmaceuticals's PEG ratio is 0.71.

-4.61
-1.74
0
1
2.57
-5.53
0.71
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 9.3, with a Debt / Equity ratio of 0.06.

9.3
9.3
0.06
-0.09
-0.12
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-865,371.24
299
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -87.91% in the last 52 weeks. The beta is 0.68, so Rocket Pharmaceuticals's price volatility has been higher than the market average.

0.68
-87.91%
5.98
12
29.1
4,497,501

Income Statement

n/a
n/a
-273.2M
-258.75M
-273.2M
-260.63M
-2.73
Full Income Statement

Balance Sheet

The company has 163.63M in cash and 25.5M in debt, giving a net cash position of 138.14M.

163.63M
25.5M
138.14M
-1.22B
471.07M
289.18M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -209.72M and capital expenditures -5.86M, giving a free cash flow of -215.59M.

-209.72M
-5.86M
-215.59M
-2.27
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

RCKT does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for RCKT is $15, which is 439.6% higher than the current price. The consensus rating is "Buy".

$15
439.6%
Buy
12
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Stock Splits

The last stock split was on Jan 5, 2018. It was a backward split with a ratio of 1:4.

Jan 5, 2018
backward
1:4

Scores

-1.99
1